Skip to main content

Scholarship opportunity

Donna sent me this press release today. She was asking if we might be able to use the service that distributed it. But, I thought I'd go ahead and post it here. Many of us with a history of the bowel issues of HPS were diagnosed with Crohn's Disease. In fact, it seems as though there's a whole debate about whether we've got Crohn's or somethng "Crohn's like." So, what do you have to lose? If you're wanting to go to school and you've got a history of HPS bowel problems, why not try?


UCB Launches $300,000 National Scholarship Program for People Living With Crohn's Disease
Scholarship Recipients From 2006 Pilot Program Announced


ATLANTA, March 1 /PRNewswire/ -- UCB, Inc. announced today the national
roll out of the 2007 Crohn's Scholarship Program, which will award 30,
one-time scholarships of up to $10,000 to people diagnosed with Crohn's
disease who demonstrate academic ambition and who are reaching beyond the
boundaries of their condition. The program is an expansion of UCB's pilot
scholarship program in 2006 that was rolled out on a smaller scale by
gastroenterologists at nine leading medical institutions across the
country. In 2006, $10,000 scholarships were awarded to 12 Crohn's patients.
Crohn's disease is a chronic and debilitating inflammatory disease of
the gastrointestinal tract, affecting more than 500,000 people in the
United States. As Crohn's disease is a chronic ailment, people go through
unpredictable periods in which the disease flares up and causes symptoms.
These episodes are followed by times of remission -- periods in which
symptoms disappear or decrease and good health returns.
"UCB has an ongoing commitment to providing patients with unique
programs and tools that help them reach beyond the boundaries of their
disease," said David Robinson, Vice President, Immunology Business Unit,
UCB. "The 2006 recipients demonstrated an astounding commitment to both
their academics and to improving the lives of others with Crohn's disease.
In expanding the scholarship program, we plan to continue assisting
students of all ages enabling them to achieve their dreams of pursuing a
college education."

The 2006 winners were chosen by a selection committee of nine leading
gastroenterologists specializing in treating Crohn's disease. Winners were
evaluated based on their essays, which highlight how they overcome the
boundaries of Crohn's disease; letters of recommendations; and their level
of academic ambition.

A 2006 winner, Gideon Sofer, demonstrated his ability to reach beyond
boundaries by working with the Make-A-Wish Foundation to help raise
awareness of Crohn's disease and its effect on daily life. After seeing how
stamps had generated much needed attention for diseases such as AIDS and
breast cancer, he worked with the foundation to call on the United States
Postal Service to commission a stamp for inflammatory bowel disease (IBD),
which includes both Crohn's disease and ulcerative colitis. Sofer met with
the U.S. Postmaster General, John Potter, and his stamp currently is under
committee review.

"I was diagnosed with Crohn's when I was 12, weighing less than 45
pounds. Not only did I hurt physically from this disease, but I was
emotionally torn because people do not like to talk about it," said Sofer.
"The UCB Crohn's Scholarship Program gives students like me an opportunity
to share our story and make a difference in life through our studies."
2006 Scholarship Recipients

-- Taylor Barbrow, a Long Grove, IL native attending Dominican University

-- Erin Coles, a Sandusky, OH native attending Bowling Green State
University

-- Bruno Frustace, a New Windsor, NY native attending Swathmore College

-- Brittney Hill, a Norwalk, OH native attending Ohio University

-- Annabel Jarman, an Acworth, GA native attending Brigham Young
University-Idaho

-- Marisa Morale, a Brooklyn, NY native attending St. Francis College

-- Simone Ovsey, a Northridge, CA native attending Massachusetts Institute
of Technology

-- Dylana Rowe, a Carrollton, CA native attending West Central Technical
College

-- Gideon Sofer, a Highland Park, NJ native attending the University of
California, Berkeley

-- John Tiley, a Hammond, LA native attending Southeastern Louisiana
University

-- Kendall Urban, an Austin, TX native attending Southern Methodist
University

-- Michael Zargham, a Troy, NY native attending Dartmouth College
Apply Now for the 2007 Program

Applications for the 2007 program are available now by visiting,
http://www.crohnsandme.com, calling 1-800-234-8770 or emailing
ucbcrohnsscholarship@srcomgroup.com. This program is designed for
applicants of any age -- from graduating high school seniors to adults
wanting to return to school to complete a masters degree. Qualifying for
the 2007 scholarship program is easy. Applicants must be:

-- A legal and permanent resident of the United States

-- Diagnosed with Crohn's disease by a physician

-- Seeking an associate's, undergraduate, or graduate degree or enrolled
in a trade school educational program

-- A student who demonstrates academic ambition and embraces a way of life
that overcomes the boundaries of living with Crohn's disease

-- Enrolled in or awaiting acceptance from a United States-based
institution of higher education for the fall semester of 2007
2007 Application Deadline and Determination of Scholarship Amount

Applications for the 2007 Crohn's Scholarship Program must be
postmarked by May 18, 2007 and the winners will be notified via phone by
UCB from July 9 through July 15, 2007. Recipients of scholarships will be
chosen by a selection committee comprised of the following medical
professionals:

-- Marla Dubinsky, M.D., Cedars-Sinai Medical Center
-- George Ferry, M.D., Texas Children's Hospital
-- Bret Lashner, M.D., Cleveland Clinic
-- Uma Mahadevan, M.D., University of California, San Francisco Center for
Colitis and Crohn's Disease
-- Scott Plevy, M.D., University of North Carolina
-- David Rubin, M.D., University of Chicago
-- Corey Siegel, M.D., Dartmouth-Hitchcock Medical Center
-- Thomas Ullman, M.D., Mt. Sinai, New York
-- Doug Wolf, M.D., Atlanta Gastroenterology Associates

Employees of UCB and their immediate family members are not eligible
for this scholarship. Selection of recipients will be at the sole
discretion of the panel members chosen by UCB. After a winner's educational
enrollment has been verified for the fall 2007 semester, the scholarship
check will be made payable to and directly mailed to the educational
institution on July 16, 2007. Scholarship amounts will be up to $10,000 to
cover the recipient's tuition and/or educational materials expenses.
However, if a student does not have a minimum of $10,000 in educational
expenses owed for his/her schooling, the scholarship amount will only cover
the remaining amount. Scholarship money cannot be used towards expenses
other than those due to the school for education expenses. If UCB learns
that an applicant does not have any remaining costs owed to the academic
institution, he/she will no longer be eligible for the scholarship. Winners
of the 2006 scholarship program are not eligible for the 2007 scholarship
program.

About UCB
UCB
(http://www.ucb-group.com) is a leading global biopharmaceutical company
dedicated to the research, development, and commercialization of innovative
pharmaceutical and biotechnology products in the fields of central nervous
system disorders, allergy/respiratory diseases, immune and inflammatory
disorders, and oncology - UCB focuses on securing a leading position in
severe disease categories. Employing over 8,500 people in over 40
countries, UCB achieved revenues of euro 2.1 billion (including net
turnover, royalties, and fees) in 2004. UCB is listed on the Euronext
Brussels Exchange with a market capitalization of approximately euro 5.8
billion. Worldwide headquarters are located in Brussels, Belgium, and U.S.
headquarters are located in Atlanta, Ga.

Comments

Popular posts from this blog

Ratner's Cheesecake

Here's another recipe from Toby! Thanks Toby......and I'll get the others posted soon! Ratner's Cheesecake and plain cookies Ratner's was a Jewish dairy restaurant in the lower East Side of Manhattan. This recipe, from my disintegrating, no longer in print Ratner's cookbook, is the closest I've ever gotten to reproducing the rich, heavy cheesecake my mother made when I was a kid. It's worth the time it takes to prepare and every last calorie. Dough Can be prepared in advance. Makes enough for two cakes. Can be frozen or used to make cookies – see recipe below. 1 cup sugar 1 teaspoon vanilla extract 1 cup shortening 1 teaspoon lemon extract 1 cup butter 2 eggs 3 cups sifted cake flour ½ teaspoon salt 2 cups all purpose flour 1 teaspoon baking powder 1. In a bowl, combine all ingredients with hands. Refrigerate 3 -4 hours, or preferably overnight. Filling (for

The next generation with Hermansky-Pudlak Syndrome

I'm so behind on posting about the trip to Puerto Rico. Since the episode of Mystery Diagnosis on Hermansky-Pudlak Syndrome ran right after we got home, it's been a little busy. These, however, are my favorite pictures from Puerto Rico. I know, not pretty senery etc - but these little guys and gals inspire me. They are the next generation of folks with HPS, and if we keep up the hard work, they will live better lives because of it. They motivate me.

Some good news about Pirfenidone

Below is a press release from Intermune, the company that makes Pirfenidone. They have essentially reviewed the various clinical trials going on, and decided that Pirfenidone is safe and well tolerated. That would pretty much go along with what we've observed in the HPS community as well. We have a few folks that have been on the drug since the late 90s and continue to do well. Of course, as a journalist, I do have to say consider the source - but at the same time, as someone in a Pirfenidone trial, it's good to know. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting - Analysis shows safety and tolerability of pirfenidone across four clinical trials - VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria